University of Pennsylvania

ScholarlyCommons
Dental Theses

Penn Dental Medicine

Winter 12-4-2020

18F-FDG-PET/CT in Radiation Therapy-Induced Parotid Gland
Inflammation
Alaa Mouminah
mouminah@upenn.edu

Follow this and additional works at: https://repository.upenn.edu/dental_theses

Recommended Citation
Mouminah, Alaa, "18F-FDG-PET/CT in Radiation Therapy-Induced Parotid Gland Inflammation" (2020).
Dental Theses. 64.
https://repository.upenn.edu/dental_theses/64

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_theses/64
For more information, please contact repository@pobox.upenn.edu.

18F-FDG-PET/CT in Radiation Therapy-Induced Parotid Gland Inflammation
Degree Type
Thesis

Degree Name
MSOB (Master of Science in Oral Biology)

This thesis is available at ScholarlyCommons: https://repository.upenn.edu/dental_theses/64

University of Pennsylvania School of Dental Medicine

18F-FDG-PET/CT

in Radiation Therapy-Induced Parotid Gland
Inflammation

Alaa Mouminah, BDS

A THESIS
Presented to the Faculty of Penn Dental Medicine in Fulfillment of the Requirements for the
Degree of Master of Oral Biology

2020
Thesis Committee

Abass Alavi, MD, PhD, DSc
Department of Radiology
University of Pennsylvania

Jonathan Korostoff, DMD, PhD
Department of Periodontics
University of Pennsylvania
School of Dental Medicine

Mona-Elisabeth Revheim, MD, PhD
Division of Radiology and Nuclear Medicine

Yu Cheng Chang, DDS, MS, DMD
Department of Periodontics

1

Oslo University Hospital, Norway

University of Pennsylvania
School of Dental Medicine

ABSTRACT
Background
18F-fluorodeoxyglucose-positron

emission tomography/computed tomography (FDG-

PET/CT) is used in the clinical management of oncologic and inflammatory pathologies.
It may have utility in detecting radiotherapy (RT)-induced damage of oral tissues. Thus,
the aim of the present study was to use FDG-PET/CT to evaluate parotid gland
inflammation following RT in patients with head and neck cancer (HNC).
Methods
This retrospective study included patients with HNC treated with photon, proton, or
combined photon/proton RT, in addition to chemotherapy. All patients received FDGPET/CT imaging pre-treatment and 3 months post-treatment. The average mean
standardized uptake value (Avg SUVmean) and the average maximum standardized
uptake value (Avg SUVmax) of the left and right parotid glands were determined by
global assessment of FDG activity using OsiriX MD software. A two-tailed paired t-test
was used to compare Avg SUVmean and Avg SUVmax pre- and post-RT.
Results
Forty-seven HNC patients were included in the study. Parotid gland Avg SUVmean was
significantly higher at 3 months post-treatment than pre-treatment (p<0.05) in patients
treated with photon RT, but no significant differences were found between pre- and
post-treatment Avg SUVmean in patients treated with proton RT or combined
photon/proton RT.
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Conclusion
Our results suggest that photon RT may cause radiation-induced inflammation of the
parotid gland, and that proton RT, which distributes less off-target radiation, is a safer
treatment alternative.
Keywords: PET/CT, 18F-FDG, Radiation therapy, Parotid gland, Parotid gland
inflammation, Head and neck cancer
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INTRODUCTION
Head and neck cancers (HNC) represent about 4% of all cancers in the United States
[1]. This group of malignancies affect a variety of anatomic structures, including the oral
cavity, oropharynx, nasopharynx, hypopharynx, larynx, paranasal sinuses, and salivary
glands [2]. Along with surgical resection and/or chemotherapy, HNC may be treated
with radiation therapy (RT) as either definitive or adjuvant treatment [2].

The majority of radiation treatment modalities for HNC consist of external beam photon
therapy, which has been associated with many systemic sequelae including
pneumonitis and vasculitis [3,4]. Oral complications of RT have proven to be very
common in cancer patients, especially those with HNC [5].Critical anatomical structures
in close proximity to the irradiated area are often affected during treatment resulting in
complications including fibrosis, taste changes, dental caries, periodontal disease, and
oral mucositis [2,6]. Because these alterations can have adverse effects on the lifestyle
and health outcomes of HNC patients, it is critical to establish an understanding of the
off-target effects of RT on the oral region which contains tissues that are particularly
susceptible to radiation-induced damage.

The parotid gland is the largest of the salivary glands and produces 60% to 65% of the
total saliva in the oral cavity. It is wrapped around the ramus of the mandible in humans
and may be an unintentional target in RT for HNC. Inflammation of the parotid gland has
been demonstrated to induce xerostomia resulting in dryness of the oral cavity [7,8]. Of
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note, radiation-induced xerostomia is the most frequently reported complications of RT
for HNC and significantly affects HNC patients’ quality of life [9].

Traditional imaging modalities such as computed tomography (CT) and magnetic
resonance imaging (MRI) have been used for staging and monitoring structural
changes. In contrast, positron emission tomography (PET) is frequently used to
visualize physiological and molecular changes [10]. 18F-fluorodeoxyglucose (FDG) is the
most commonly used tracer for PET scanning. It is a radiolabeled glucose analog, taken
up by cells that rapidly consume and metabolize glucose, such as cancer and
inflammatory cells [11–13]. The fused FDG-PET/CT allows for detection and
quantification of glucose metabolism on the molecular level leading to a more accurate
detection of malignancies and inflammatory changes in the head and neck [14,15] .

LITERATURE REVIEW
Proton Radiotherapy is a specialized technique that is not available to a large number of
patients. As proton radiotherapy becomes more accessible, studies reporting clinical
outcomes are becoming steadily important. The maximum dose of photons are near the
surface followed by a continuous reduction in dose with depth. This physical advantage
of protons over photons is highly important. On the other hand, proton beam energies
can produce a spread out that covers the tumor accurately and delivers a lower dose to
normal tissues beyond the tumor. These features allow for better target dose delivery
than photon techniques.
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In a nonrandomized retrospective study by Baumann et al. they compared the
effectiveness of proton versus photon in HNC patients. The study included 1483 adult
patients with locally HNC advanced cancer treated with chemoradiotherapy and
received proton or photon therapy. The objective was to assess whether proton therapy
is associated with fewer unplanned hospitalizations or other adverse events and similar
disease-free and overall survival compared with photon therapy. In this analysis, they
concluded that proton chemoradiotherapy was associated with significantly reduced
acute adverse events that caused unplanned hospitalizations, with similar disease-free
and overall survival.[16]
As our main focus is salivary glands, this study conducted by Grant et al. is the only
study reporting on outcomes for salivary gland tumors but in the pediatric population
comparing proton versus photon radiotherapy. They retrospectively analyzed 24 cases
of pediatric salivary gland tumors and found that proton therapy was associated with a
favorable acute toxicity. When they compared proton to conventional radiotherapy, they
detected that patients who received proton therapy experienced significantly less acute
mucositis and a trend toward significantly less dysphagia and weight loss. Also, proton
therapy was associated with reduced dose to several surrounding normal structures
relative to photon therapy. In this study of pediatric salivary tumors, they revealed that
proton therapy is associated with favorable outcomes. This finding highlights the
advantage of proton therapy, which is in reduced exit but not entrance dose.[17]

A systematic review was performed to retrieve evidence on late treatment toxicity for
carbon-ion, proton and photon radiotherapy. They included eight comparative studies
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and 86 observational studies. Although poorly reported, toxicity tended to be less
frequent in carbon-ion and proton studies compared to photons. No late xerostomia or
dysphagia were observed in proton radiotherapy related results. Protons can be used to
deliver a lower normal tissue dose while keeping the target dose similar, so the control
of the tumor is anticipated to be similar to the results of photon radiotherapy. There is a
strong depended relation between the severity of radiation-induced side effects and the
dose and volume of the radiation area, where it will likely be less in proton
radiotherapy.[18]

Much of the existing literature on the clinical application of FDG has focused on the
radiotracer’s utility in diagnosing malignancies due to the typically increased glucose
metabolism of cancer cells, but FDG has also been used for decades to detect
inflammatory processes. Therefore, we predict that FDG-PET/CT will show potential in
the evaluation of radiation-induced inflammation in the parotid gland that predisposes
patients to xerostomia.

A retrospective study by Roach et al. in patients with head and neck squamous cell
carcinoma (HNSCC) aimed to identify the relationship of radiation dose response of
parotid gland glucose metabolism. They used the same technique we are proposing in
our present study, but the pretreatment and post treatment scans varied between 3 and
6 months. They aimed to identify a threshold radiation dose where the parotid gland
activity declined. The mean dose threshold in this study was 32 Gray.[19]
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As we discussed previously, most of the existing literature aims to identify the radiation
dose– response relationship of parotid gland in head and neck cancer patients using
FDG-PET imaging. In our study we predict that FDG-PET/CT will show potential in the
evaluation of radiation-induced inflammation in the parotid gland that predisposes
patients to xerostomia regardless of the radiation dose because we are focusing on the
type of radiotherapy.

18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDGPET/CT) is used in the clinical management of oncology and inflammatory pathologies.
It may have utility in detecting RT-induced damage of oral tissues. In effort to confirm
the correlation between FDG uptake, parotid gland inflammation, and saliva production.
The aim of the present study is to demonstrate the feasibility of FDG-PET/CT in the
detection and quantification of the inflammatory effect of RT on the parotid gland in
HNC patients.

MATERIALS AND METHODS
Patient Population
Between 02/09/2010 and 11/27/2018, 64 patients with HNC treated with photon, proton,
or combined photon/proton RT, in addition to chemotherapy with either cisplatin or
cetuximab at the University of Pennsylvania. All patients were imaged pre- and 3
months post-treatment with FDG-PET/CT. Of the 64 patients, 17 were not included in
the study due to technical issues associated with their FDG-PET/CT scans, inferior
imaging quality in the head and neck region and/or mismatch between PET and CT
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images. The collected clinical data included age, sex, and primary tumor location. The
primary tumor locations were tongue, larynx, oropharynx, nasopharynx and
hypopharynx. PET/CT scans used for the study were free from background noise,
scatter, and metal artifacts. The study was approved by the Institutional Review Board.
It was conducted in compliance with the Health Insurance Portability and Accountability
Act (HIPAA).

FDG-PET/CT Image Acquisition
All subjects were injected intravenously with 5.0 MBq/kg FDG. After approximately 60
minutes FDG-PET/CT images were obtained using the same standardized protocol.
Imaging was performed on hybrid PET/CT scanners with comparable spatial resolution
(Siemens Biograph 64 mCT (Siemens Healthineers AG, Chicago, IL, USA) and Philips
Gemini TF 16 (Philips Medical Systems, Andover, MA, USA)). The images were
acquired in accordance with international guidelines[33,34] and the institutional PET/CT
protocol, including quality control, calibration and harmonization of PET/CT scanners
and validation of standardized uptake value (SUV) measurements. Patients fasted for
at least 6 hours prior to scanning and serum glucose levels were immediately measured
prior to FDG injection. Three acquisition protocols were used: one for body mass index
(BMI) under 30, another for BMI between 30 and 35, and the third BMI over 35; the CT
settings were 50, 100 and 150 mAs, respectively and all at 120 kVp. For the PET
acquisitions, the time per bed was 1.5, 2, and 3 minutes, respectively. Low-dose CT
imaging was performed for anatomic localization and attenuation correction. PET
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images were corrected for scattering, attenuation, scanner dead time, and random
coincidences.

FDG-PET/CT Image Analysis
FDG-PET/CT scans were analyzed using OsiriX MD software v.10.0.2 (DICOM viewer
and image-analysis program, Pixmeo SARL; Bernex, Switzerland). Sequential axial
PET/CT slices were used to draw regions of interest (ROI) manually around the right
and left parotid glands using a closed polygon (Figure 1). The reader was blinded to the
paired PET scans (pre- and post-treatment scans). Parotid gland ROIs were drawn
beginning superiorly at the level of condyle down to the angle of the mandible inferiorly.
The skin and external ear were defined as the lateral borders, the styloid process of the
temporal bone was the medial border, and the mastoid process of the temporal bone
was the posterior border.

The SUVmean was calculated as the average value of all voxels in the ROI. To
determine the global activity of the parotid gland, the SUVmean as well as area (mm 2)
of each ROI at each transverse slice, was measured and recorded. The SUVmean was
multiplied by the area, and the products were summed, the result of which was divided
by the sum of the total area of the ROIs (Sum (SUVmean*Area))/(Sum Area). This
resulted in the average SUVmean (Avg SUVmean) representative of a global
inflammation burden of the parotid gland. The SUVmax was defined as the hottest voxel
within the ROI. The average SUVmax (Avg SUVmax) represented the average value
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from all trans-axial slices which include both right and left parotid glands. Statistical
comparison was completed by using the Avg SUVmean and Avg SUVmax of all slices.

Statistical Analysis
For each subject, pre- and post-treatment Avg SUVmean and Avg SUVmax was
calculated. A two-tailed paired t-test in STATA software (Stata/IC Version 10.1,
StataCorp, College Station, TX) was used to compare the Avg SUVmean and Avg
SUVmax in the pre- and post-treatment scans. The level of significance was defined as
a p-value of less than 0.05. The average mean increases in SUVmean and SUVmax
were calculated by subtracting pre-treatment from post-treatment Avg SUVmean and
Avg SUVmax values for each patient.

RESULTS
The data collected from a total of 47 HNC patients (25 males, 22 females), mean age
59.7 years (range 42-78) with pre and post-treatment FDG-PET/CT were included.
Thirty-three patients were in the photon RT group, while seven patients were in each of
the proton RT and combined photon/proton RT groups. Primary tumor location, age,
gender, and race are summarized in Table 1.

Statistical data are summarized in Table 2 and 3. The parotid gland Avg SUVmean in
patients treated with photon RT was significantly higher in post-treatment scans (1.50,
p<0.05) relative to those done pre-treatment (1.38, p<0.05) (Figure 2). The Avg
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SUVmax was higher in post-treatment scans (2.06) compared to those done pretreatment (1.96), but the difference was not statistically significant.

In patients treated with proton RT, the parotid gland Avg SUVmean was not significantly
different in post-treatment scans (1.32, p>0.05) when compared to pre-treatment scans
(1.25, p>0.05) (Figure 3). Evaluation of pre- and post-treatment scans for Avg SUVmax
yielded a similar finding (post-treatment [1.73, p>0.05] and pre-treatment [1.72,
p>0.05]).

Analysis of the parotid gland Avg SUVmean in patients treated with combined
photon/proton RT was not significantly different in post-treatment scans (1.32, p>0.05)
when compared to pre-treatment scans (1.25, p>0.05) (Figure 4). Similar findings were
presented for Avg SUVmax (post-treatment [2.12, p>0.05] and pre-treatment [1.90,
p>0.05]).

DISCUSSION
Our study demonstrates a significant increase in FDG uptake in the parotid glands of
HNC patients following photon RT and chemotherapy treatments. Investigating the
impact of these treatments on the parotid gland is critical, not only because of its role in
saliva production but also due to the fact that cranial nerve VII (facial nerve) lies in close
proximity to and innervates the gland. This nerve also innervates numerous muscles of
facial expression, as well as the stylohyoid and posterior belly of the digastric muscles,
which play a critical role in swallowing [20]. The glossopharyngeal nerve provides
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parasympathetic innervation to the parotid gland, as well as sensory innervation to the
posterior one-third of the tongue and pharynx. Photon RT and/or chemotherapy induced
damage of the parotid gland can therefore impact glossopharyngeal nerve function and
indirectly lead to deleterious effects on adjacent structures in the head and neck region
[21]. Thus, determining the FDG uptake in the parotid gland is of clinical
interest/importance in investigating potential previously underappreciated side effects of
radiotherapy in head and neck cancer patients.

In our study, we found that Avg SUVmean was significantly higher in the parotid gland
following photon RT, but not in patients who underwent proton RT or combined
proton/photon RT. Although Avg SUVmean was significantly increased in patients
receiving photon RT, SUVmax values were not significantly different in pre-treatment
versus post-treatment scans of patients receiving any form of RT. SUVmax is the
maximum voxel value of SUV in the target structure/ROI. SUVmax is simple and
observer independent, hence SUVmax is the most commonly used parameter in clinical
practice. However, SUVmax does not represent an entire structure`s metabolic burden
because the value is from only one voxel. Furthermore, SUVmax is sensitive to image
noise, and is therefore impacted by various patient characteristics and imaging
parameters. On the other hand, Avg SUVmean accounts for all uptake within the ROIs
and is more reflective of the total pathological changes in glucose metabolism, which
suggests that Avg SUVmean is a more accurate value to use in this data collection.
Since we suspect that radiation-induced parotid injury is a diffuse pathology that has the
potential to elicit an inflammatory response across the entire gland, we used the Avg
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SUVmean as it is likely to be a more accurate indicator of the extent of the global
inflammation.

There are several artifacts encountered in PET/CT imaging including attenuation
correction artifacts commonly associated with the use of CT. Attenuation correction
algorithms work well for most applications in the majority of patients. However, these
algorithms tend to overcorrect objects that have higher density but are not true bone
pixels. Dental implants or fillings can cause such an attenuation correction artifact and
can confound image interpretation and effect the quantification in the head and neck
region. In the present study, of the 64 patients, 17 were not included in the study due to
technical issues including the presence of artifacts related to metallic based
restorations, orthodontic appliances, and other dental procedures which are the main
cause of beam hardening. This confirms the lack of beam hardening artifact effect on
our measurements.

We assert that the increased FDG uptake observed in this study was a result of RTinduced inflammation in the parotid gland. Cellular uptake of FDG is a marker for
inflammation, and these results confirm its utility in identifying parotid gland pathology
following RT in head and neck cancer patients. In classic parotitis, this inflammation is
most often the result of a localized infection or cellular damage, though the irritation can
be caused by a myriad of factors, including pathogenic microbes derived from the oral
cavity, metabolic imbalances, and autoimmune disorders [22]. Initiation of inflammatory
processes in the gland can lead to a decrease in salivary production, causing
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dehydration of the gland as well as a distortion of the parotid duct and metaplasia of the
ductal epithelium [23]. Uptake of FDG may begin to increase subsequent to the
preliminary irritation and continue to increase as the inflammatory response progresses
[23]. Since RT has been shown to increase systemic inflammation, patients experience
a significant risk in the perturbation of the parotid gland, since it is particularly
susceptible to irritation [24,25].

It is critical to acknowledge the limitations of our study. This was a retrospective
analysis with a relatively small sample size of patients. Thus, future evaluation of the
use of FDG-PET/CT as a surrogate measurement of inflammatory activity in the parotid
gland after RT treatment should be directed towards prospective studies using large
numbers of patients. Information regarding full tumor stage, type of radiation field, the
exact dosage of radiotherapy administered to patients, and oral complications were not
available for the current study, which limited the description of our patient cohort. A
survey reported that 64% of at least 3 years survivors after RT suffered from moderate
to severe xerostomia [26]. Thus, future studies must include detailed information
regarding the occurrence of xerostomia in order to determine whether increased
parotid-uptake of FDG can be used to predict the onset of this condition. Partial volume
effect, which accounts for signal overlap from neighboring anatomical structures and
potential movement of the patients during scan acquisition, may have altered the data
used in these analyses. Therefore, the regions used as borders in determining the
extent of the ROIs may have been ambiguous, depending on the quality of the scan.
The influence of partial volume effect is due to the limited resolution of the technology
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used in obtaining these scans [27,28]. This could account for the single outlier
observed in the data, which might have introduced further uncertainty into the results
(Figure 2). In addition, because the patients who participated in the study received both
chemotherapy and photon RT, it is not possible to differentiate between the
inflammatory effects of each treatment individually. Finally, there were only two-time
points assessed in this study, pre-treatment and 3 months post-treatment, which
prevented the evaluation of FDG uptake throughout the entire post-treatment period.

The present study suggests that an increase beyond normal physiological glucose
uptake in the parotid gland occurs as a manifestation of RT-induced inflammation.
Given that inflammation is followed by cell damage and fibrosis of some of the glandular
tissue [29], we predict that additional follow-up scans will demonstrate a decrease in the
parotid gland uptake due to lack of normal gland activity and function. It would be
helpful to direct future studies towards more longitudinal assessments of FDG uptake in
the parotid gland to better track changes in signaling over time to determine the time
frame of cell damage and fibrosis manifesting as a decline in parotid gland function
compared to pre-treatment.

Protocols utilizing photon beams are currently the most common form of RT for HNC
while less than 1% of patients are treated with proton therapy [30]. When comparing
proton to photon therapy, proton therapy reveals an added advantage of lower dose and
smaller number of beams [31]. In the present study, no significant differences were
found between pre- and post-treatment parotid FDG uptake in patients treated with
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proton RT. This observation might be indicative of there being less radiation delivered to
normal tissues in close proximity to actual tumors thereby minimizing collateral toxicity
and limiting the extent of side effects traditionally associated with photon-based RT
[30,32].

The present study demonstrated significantly higher FDG uptake in the parotid glands of
patients undergoing photon-based RT for treatment of HNC. This increase in glucose
metabolism may be indicative of radiation-induced inflammation, which subsequently
can progress result in decreased functionality of the parotid gland. Future studies
should include a larger sample to allow comparison of the effect of photon RT for
treatment of HNC to other modalities of RT in order to assess the differential impact on
parotid gland function. Confirmation of the correlation between FDG uptake and saliva
production might enable clinicians to choose alternative RT regimens and/or intervene
at an earlier stage and prevent the sequela of xerostomia.

CONCLUSION
FDG-PET/CT has the potential to be used to measure the metabolic activity associated
with RT-induced inflammation and predictor of parotid gland dysfunction.

LIST OF ABBREVIATIONS
•

FDG-PET/CT: 18F-fluorodeoxyglucose-positron emission tomography/computed
tomography.

•

RT: radiotherapy.
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•

HNC: head and neck cancer.

•

CT: computed tomography.

•

MRI: magnetic resonance imaging.

•

PET: positron emission tomography.

•

FDG: 18F-fluorodeoxyglucose.

•

HIPAA: Health Insurance Portability and Accountability Act.

•

SUV: standardized uptake value.

•

Avg SUVmean: average mean standardized uptake value.

•

Avg SUVmax: average maximum standardized uptake value.

•

ROI: region of interest.

•

BMI: body mass index.
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Table 1. Primary tumor location, age, gender, and race.
Number of Patients
Primary Tumor

Males

Females

Location

Race
Average Age

White

African
American

Other

(Years)

Tongue

14

3

61.97

15

2

0

Larynx

3

2

54.66

4

0

1

Oropharynx

3

14

58.70

13

3

1

Nasopharynx

3

2

58.25

3

1

1

Hypopharynx

2

1

62.73

2

0

1
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Table 2. Parotid gland average mean standardized uptake value (Avg SUVmean) and
in head-and-neck cancer patients pre- and post-treatment scans.

Avg SUVmean
(g/mL)

Pre-treatment

Post-treatment

P-value

Photon Therapy

1.38

1.50

0.03

Proton Therapy

1.25

1.32

0.31

Combined Therapy

1.51

1.46

0.40
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Table 3. Parotid gland average maximum standardized uptake value (Avg SUVmax)
and in head-and-neck cancer patients pre- and post-treatment scans.

Avg SUVmax
(g/mL)

Pre-treatment

Post-treatment

P-value

Photon Therapy

1.96

2.06

0.18

Proton Therapy

1.72

1.73

0.50

Combined Therapy

1.90

2.12

0.21
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Figure 1. 18F-fluorodeoxyglucose positron emission tomography/computed tomography
(FDG-PET/CT) images of the parotid gland. Left: Fused FDG PET/CT, right: CT. The
delineation of the region of interest (ROI) is highlighted for the right and left parotid
glands.

27

Figure 2. Changes in average standardized uptake value mean (Avg SUVmean) of the
parotid gland before and 3 months after treatment in patients treated with photon RT.

28

Figure 3. Changes in average standardized uptake value mean (Avg SUVmean) of the
parotid gland before and 3 months after treatment in patients treated with proton RT.
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Figure 4. Changes in average standardized uptake value mean (Avg SUVmean) of the
parotid gland before and 3 months after treatment in patients treated with combined
photon/proton RT.
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